US-based contract research organisation (CRO) Quintiles Transnational has boosted its capabilities in the fast-growing market for targeted oncology therapies by acquiring fellow US company Targeted Molecular Diagnostics (TMD).

Headquartered in Westmont, Illinois, TMD is a privately held specialist diagnostic laboratory serving the pharmaceutical industry and focused on oncology. The company supports the development of “numerous” targeted cancer therapies, providing guidance through biomarker expression analysis and helping to cut timelines and costs for bringing new compounds to market, Quintiles said.

The acquisition provides strong capabilities in tissue-based testing testing, a “critical component of the modern oncology drug development process”, the CRO noted. TMD offers more than 100 biomarker assays, which will “help Quintiles’ customers better understand how their drugs work and in which populations they’re most likely to perform best”, it explained.

Founded in 2004 by president and chief executive officer Dr Sarah Bacus, TMD is currently involved in clinical trials for pharmaceutical and biotechnology companies in over 40 countries.

Tom Wollman, senior vice president, Quintiles Global Central Laboratories, described the acquisition as “a logical addition to Quintiles’ service offerings”. It “provides us with advanced in-house pathology capabilities, including telepathology,” he commented. “Most importantly, TMD’s knowledge in biomarker expression analysis adds significant new proficiencies sought by our customers.”

The combination of TMD’s oncology expertise and Quintiles’ global reach should make for “exceptional service delivery”, Bacus said.